Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04447222 · ClinicalTrials.gov registry record

Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors

A clinical trial of Malignant Solid Neoplasm and COVID-19 Infection, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
1,242
Enrollment target
1
Study location

NCT04447222: Active study of Malignant Solid Neoplasm and COVID-19 Infection, sponsored by M.D. Anderson Cancer Center.

NCT04447222 is a study of Malignant Solid Neoplasm and COVID-19 Infection that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,242 participants, above the 1,134-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04447222, a study of Malignant Solid Neoplasm and COVID-19 Infection, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
1,242 participants
Enrollment target
1
Study location

Study Summary

This study uses questionnaires to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted health-related quality of life (HRQOL) and other areas such as COVID-19-specific psychological distress, disruptions to health care, finances and social interactions in cancer patients. The coronavirus disease 2019 (COVID-19) is an infectious disease that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The information learned from this study will guide the development of psychosocial programs to improve patient care and outcomes in cancer patients and survivors in the context of facing a global pandemic.

Primary Outcome

Assessed using a COVID-19 questionnaire. Responses are provided on a Likert scale (from 1 to 4) where participants are asked to rank statements from "strongly disagree" to "strongly agree.''

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Survey Administration
  • OTHER Questionnaire Administration

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 1,242 participants
Start Date 2020-05-12
Est. Completion 2026-07-30
M.D. Anderson Cancer Center

2,692 total trials

What the registry record for NCT04447222 still lists

NCT04447222 is an observational study that tracks outcomes without assigning an intervention. Its 1,242 participants enrollment target places it among the larger protocols in the corpus, above the 1,134-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (10% higher).

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.

NCT04447222 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04447222 about?

NCT04447222 is a clinical study titled "Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors". This study uses questionnaires to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted health-related quality of life (HRQOL) and other areas such as COVID-19-specific psychological distress, disruptions to health care, finances and ...

What is the current status of trial NCT04447222?

This trial is currently active not recruiting. The enrollment target is 1,242 participants. The study started on 2020-05-12. Estimated completion is 2026-07-30.

What conditions does trial NCT04447222 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, COVID-19 Infection.

What interventions are being tested in trial NCT04447222?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Survey Administration (OTHER), Questionnaire Administration (OTHER).

Who is sponsoring clinical trial NCT04447222?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04447222 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04447222's enrollment target sits among peer trials

1,242 18th of 176 higher than 159 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06368245 · 1,244 participants

    Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions

  • NCT02743858 · 1,250 participants

    Lymphedema Surveillance Study

  • NCT04670874 · 1,250 participants

    Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29

  • NCT04807868 · 1,250 participants

    AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04447222, the US trial registry maintained by the National Library of Medicine. NCT04447222 (large enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.